A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The decision builds on previous FDA approval for the drug’s treatment when combined with additional oral antidepressants. While Spravato’s underlying mechanisms remain unclear and only be ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved... The U.S. Food and Drug Administration has ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Alkermes is now planning to meet with the FDA in the coming months to work out its next steps - and see if there is a potential path forward for the antidepressant programme. CEO Richard Pops said ...

Getty Images Patients could experience improvements in their symptoms as early as 24 hours without the need for daily oral antidepressants. The approval, granted following FDA priority review ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

The original approval required that patients on Spravato also receive an oral antidepressant. Now, the FDA says the drug can be used on its own. The decision came after a large study found that ...